Today: 20 June 2026

Credo Technology (CRDO) stock climbs as AI-chip trade stays hot; Needham conference next

Credo Technology (CRDO) stock climbs as AI-chip trade stays hot; Needham conference next

Credo Technology shares rose 3.1% to $155.10 Monday, trading as high as $156.43 amid sector gains and anticipation of its Jan. 14 presentation at Needham’s Growth Conference. The company last reported $268 million in quarterly revenue and forecast up to $345 million for the next period. TSMC will report earnings Jan. 15, with investors watching for AI chip demand signals.
12 January 2026
···
Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony shares fell 8.2% to $79.76 after Donald Trump called for a one-year 10% cap on credit card interest rates, sparking fears of tighter regulation and profit declines. Analysts said such a cap would require congressional approval. Bread Financial, Capital One, and Barclays also saw declines. Separately, Synchrony expanded CareCredit integration with Fiserv’s Clover platform, now reaching over 40,000 providers.
12 January 2026
·
Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments shares slipped 0.2% to $189.85 in Monday afternoon trading, underperforming chip sector peers as the iShares Semiconductor ETF rose 0.7% and Nvidia gained about 1%. Investors are watching TI’s Jan. 27 earnings for signals on industrial and auto demand amid market volatility tied to a Justice Department probe involving Fed Chair Jerome Powell.
12 January 2026
····
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics shares fell 11% to $17.46 Monday after announcing a U.S. FDA biologics license application for its lung cancer drug ivonescimab. The company also disclosed a clinical trial collaboration with GSK to test a combination regimen in solid tumors. Investors are watching for the FDA’s next procedural step and updates from the J.P. Morgan Healthcare Conference.
12 January 2026
·
Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Figure Technology Solutions shares fell 9.6% to $52.50 Monday after releasing preliminary Q4 metrics. The company reported $2.705 billion in Q4 consumer loan marketplace volume, up 131% from a year earlier, and $328 million in $YLDS stablecoin circulation. Investors are watching for Tuesday’s U.S. CPI report and the Fed’s January meeting for rate signals.
12 January 2026
··
Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial shares fell 10.8% to $71.65 Monday after Donald Trump proposed a one-year 10% cap on credit card interest rates, with no details on enforcement. The selloff spread to other lenders, including Synchrony and Capital One. Analysts questioned the proposal’s viability, citing legal hurdles. Bread Financial reports earnings Jan. 29, with investors watching for commentary on policy risks.
12 January 2026
·····
Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

Lululemon shares rose 3.2% to $210.43 Monday after the company said holiday-quarter revenue and profit would reach the high end of its forecast, citing strong seasonal demand. The retailer maintained its margin and expense outlook. CEO Calvin McDonald steps down Jan. 31, with interim co-CEOs named as the board searches for a replacement. Founder Chip Wilson has launched a proxy fight as Elliott Management builds a $1 billion stake.
12 January 2026
··
GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx shares fell about 14% to $115.75 Monday after releasing preliminary 2025 results and 2026 revenue guidance above analyst estimates. The company projected 2026 revenue of $540–$555 million and positive adjusted net income. Investors are awaiting CEO remarks at the Jan. 14 J.P. Morgan Healthcare Conference and the Feb. 23 earnings report for further details. The latest figures remain unaudited and subject to revision.
12 January 2026
·
Honeywell stock flat as new Google Cloud retail tech lands, Citi trims target ahead of earnings

Honeywell stock flat as new Google Cloud retail tech lands, Citi trims target ahead of earnings

Honeywell shares edged up 0.1% to $207.50 after launching new software tools for retail and warehouse operations. Citi lowered its price target to $262 but maintained a buy rating. Investors await Honeywell’s Jan. 29 results and 2026 outlook for signs of demand and margin trends. Honeywell will start rolling out its new Smart Shopping Platform in February.
12 January 2026
··
D.R. Horton stock rises as KBW trims target — what Wall Street is watching next

D.R. Horton stock rises as KBW trims target — what Wall Street is watching next

D.R. Horton shares rose about 1% to $158.82 Monday afternoon, tracking gains in other major homebuilders. Keefe Bruyette & Woods cut its price target on the stock to $168 from $175 but kept a “Market Perform” rating. Investors are focused on D.R. Horton’s Jan. 20 earnings after the company warned that affordability pressures could keep sales incentives high in 2026.
12 January 2026
·····
SoFi stock slides as CEO Anthony Noto weighs Trump’s 10% credit-card rate cap

SoFi stock slides as CEO Anthony Noto weighs Trump’s 10% credit-card rate cap

SoFi Technologies shares fell 2.4% to $26.74 Monday after CEO Anthony Noto said Trump’s proposed 10% cap on credit-card rates could boost demand for personal loans. The stock had reached $28.05 before reversing. Capital One and Synchrony dropped 7.5% and 8.9%, while Visa and Mastercard each lost about 2%. Trump’s plan would cap rates for one year starting January 20.
12 January 2026
··
Nike stock dips even after Jefferies’ “buy aggressively” call — what NKE investors are watching next

Nike stock dips even after Jefferies’ “buy aggressively” call — what NKE investors are watching next

Nike shares fell 0.6% to $65.52 Monday afternoon, underperforming the broader market despite Jefferies reaffirming its buy rating and $110 price target ahead of the ICR conference. Nike’s latest quarter showed revenue up 1% to $12.4 billion, but net income dropped 32% and gross margin fell to 40.6% due to higher tariffs. Wholesale revenue rose, while direct and Converse sales declined.
12 January 2026
··
Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade shares jumped 7.7% to $85.81 Monday, hitting a new 52-week high amid heavy short interest and volatile trading. About 20% of the float was shorted as of mid-December, raising the risk of sharp moves. Chief insurance officer John Peters sold 10,000 shares Jan. 6 at $80 under a pre-set plan. The next earnings report is expected Feb. 24.
12 January 2026
··
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta Therapeutics shares fell 13% to $20.73 Monday after a preliminary update showed weaker-than-expected fourth-quarter sales for its Duchenne gene therapy, Elevidys. The company reported $110.4 million in Elevidys revenue for the quarter, below Wall Street’s $122 million estimate. Sarepta cited a severe flu season and delayed six patient infusions to 2026. Final results are due in late February.
12 January 2026
·
Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch shares fell 17.3% to $103.26 after the company cut its full-year sales growth forecast and lowered its holiday-quarter outlook. The retailer now expects fiscal 2025 net sales growth of at least 6%, down from a prior 6%–7% range, and factored in $90 million in tariff expenses. Investors are watching the ICR Conference this week for further updates on demand and pricing.
12 January 2026
·
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck shares fell 1.1% to $109.27 Monday amid speculation over a possible $28–32 billion acquisition of Revolution Medicines, though no deal has been finalized. The SPDR S&P Biotech ETF dropped 2.1%. Analysts estimate Revolution’s RAS inhibitor drugs could generate over $10 billion in sales by 2035. Merck also faces a potential $2 billion annual revenue hit after U.S. vaccine schedule changes affecting Gardasil and RotaTeq.
12 January 2026
··
Goldman Sachs stock ticks up as Powell probe threat, rate-cap talk keep banks on edge

Goldman Sachs stock ticks up as Powell probe threat, rate-cap talk keep banks on edge

Goldman Sachs shares rose 0.6% to $944.73 in Monday afternoon trading ahead of fourth-quarter earnings due Jan. 15. Markets weighed Trump’s proposed 10% cap on credit-card interest rates and threats to indict Fed Chair Jerome Powell. Traders are focused on Tuesday’s U.S. CPI report and major bank earnings. Goldman’s chief economist now expects Fed rate cuts in June and September.
12 January 2026
···
1 … 885 886 887 888 889 … 2,086

Stock Market Today

  • Satoshi Nakamoto Holds Largest Bitcoin Stake Worth $72 Billion
    June 20, 2026, 9:58 AM EDT. Data from Arkham Intelligence reveals that Satoshi Nakamoto, Bitcoin's pseudonymous creator, remains the largest individual holder of Bitcoin. Despite the cryptocurrency's extensive trading and market fluctuations, Nakamoto has never sold any of the coins, maintaining a portfolio valued at approximately $72 billion. This vast holding underscores Nakamoto's significant influence on the Bitcoin market, although the identity of this holder remains unknown.

Latest articles

SpaceX ETF Rush Hits Retail Risk Nerve After Record IPO

SpaceX ETF Rush Hits Retail Risk Nerve After Record IPO

20 June 2026
SpaceX shares closed Thursday at $185, still well above the $135 IPO price but down 3.6% on the day, after more than $10 billion traded in leveraged ETFs and ARK Innovation ETF saw record $4.6 billion inflow and $6.2 billion outflow around the IPO, highlighting intense volatility and rapid ETF-driven trading that could magnify both gains and losses for investors.
Pennsylvania gas prices near U.S. average ahead of July Fourth

Pennsylvania gas prices near U.S. average ahead of July Fourth

20 June 2026
Pennsylvania gasoline prices dropped 53.5 cents in a month to $4.109 a gallon, AAA data show, just before July Fourth travel; relief is driven by eased crude prices after a U.S.-Iran Strait of Hormuz deal, but state prices remain 74 cents above last year and 16 cents above the U.S. average, with supply risks and refinery bottlenecks threatening further declines.
JBS Plant Shutdowns Draw Attention to Beef Supply Limits Again

JBS Plant Shutdowns Draw Attention to Beef Supply Limits Again

20 June 2026
JBS USA will close its Souderton, PA beef plant and Memphis meat facility as tight cattle supplies and weak packer margins pressure the industry; the Souderton shutdown affects 1,485 workers and handles about 2,000 cattle daily, while JBS North American beef operations posted a $267 million negative adjusted EBITDA last quarter despite higher revenue.
Go toTop